AFM-21

N/A

Report date: 2026/03/19 16:57:34

Base Information

Drug NameAFM-21

Drug Alias NameEGFRvIII TandAbsanti-CD3/anti-EGFRvIII bispecific T-cell engager (Affimed)AFM-21

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsEpidermal growth factor receptor erbB1 modulators

TargetsEpidermal growth factor receptor erbB1T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAffimed Nv

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAffimed Nv

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A